-
EP1476120
European procedure
Extract from the Register of European Patents
EP Citations: EP1476120
| Cited in | Search | Type: | Patent literature | Publication No.: | US5484892
[DX] (TEDDER THOMAS F [US], et al) [DX] 1-43 * column 3, line 4 - line 42 * * column 5, line 61 - line 67 * * column 6, line 1 - line 7 * * column 8, line 57 - line 62 * * column 10, line 28 - line 67 * * column 11, line 1 - line 17 * * column 16, line 8 - line 11 * * column 16, line 33 - line 35 * * tables II,III,IV,V *; | Type: | Patent literature | Publication No.: | WO03072736
[L] (UNIV DUKE [US], et al) [L] 1-43* the whole document *; | Type: | Non-patent literature | Publication information: | [X] - LEONARD J P ET AL, "EPRATUZUMAB, A NEW ANTI-CD22. HUMANIZED, MONOCLONAL ANTIBODY FOR THE THERAPY OF NON-HODGKIN'S LYMPHOMA (NHL): PHASE I/II TRIAL RESULTS", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, (19991115), vol. 94, no. 10 SUPPL PART 1, ISSN 0006-4971, pages 92A - 93A, XP000929541 [X] 1-39 * the whole document * | Type: | Non-patent literature | Publication information: | [A] - STEIN R ET AL, "EPITOPE SPECIFICITY OF THE ANTI-(B CELL LYMPHOMA) MONOCLONAL ANTIBODY LL2", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, (1993), vol. 37, no. 5, ISSN 0340-7004, pages 293 - 298, XP002070322 [A] 1-39 * page 296, column RIGHT, line 3 - line 27 * | DOI: | http://dx.doi.org/10.1007/BF01518451 | Cited in | International search | Type: | Patent literature | Publication No.: | US5484892
[Y] (TEDDER THOMAS F [US], et al) | Cited in | Examination | Type: | Non-patent literature | Publication information: | - CARNAHAN JOSETTE ET AL, "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 SEP 2003, (20030901), vol. 9, no. 10 Pt 2, ISSN 1078-0432, pages 3982S - 90S | Type: | Non-patent literature | Publication information: | - LEONARD JOHN P ET AL, "Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 15 AUG 2003, (20030815), vol. 21, no. 16, ISSN 0732-183X, pages 3051 - 3059 | Cited in | by applicant | Type: | Non-patent literature | Publication information: | - "EPRATUZUMAB, A NEW ANTI-CD22, HUMANIZED, MONOCLONAL ANTIBODY FOR THE THERAPY OF NON-HODGKIN'S LYMPHOMA and PHASE I/II TRIAL RESULTS", LEONARD J P ET AL., BLOOD, W.B. SAUNDERS, (19991115), vol. 94, pages 92A - 93A |